Market Overview

Goldman Says FDA Response to Energy Drink Safety Review 'Encouraging' for Monster

Share:
Related MNST
San Francisco Not So Sweet To Beverage Investors
The Investment Case Against Sugar
Steve Mandel Buys Allergan, Baxalta, PayPal (GuruFocus)

Commenting on the action in Monster Beverage this afternoon, Goldman Sachs analyst Judy Hong called the FDA's response to the energy drink safety issue "generally benign." Hong believes this should be encouraging for Monster. The analyst believes the most likely outcome related to Durbin's energy drink review will be strong labeling, something which is unlikely to have a material impact on Monster.

Latest Ratings for MNST

DateFirmActionFromTo
Mar 2016Bank of AmericaInitiates Coverage onNeutral
Mar 2016Goldman SachsUpgradesBuyConviction Buy
Feb 2016CLSAUpgradesOutperformBuy

View More Analyst Ratings for MNST
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings Movers

 

Related Articles (MNST)

View Comments and Join the Discussion!